Crinetics Pharmaceuticals: Strong Financial Position and Promising Pipeline Drive Buy Rating

Crinetics Pharmaceuticals (CRNX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Cory Jubinville, PhD from LifeSci Capital maintained a Buy rating on the stock and has a $82.00 price target.

Cory Jubinville, PhD’s rating is based on several promising developments within Crinetics Pharmaceuticals’ pipeline. The company has reported a strong financial position with $1.3 billion in cash, which is expected to sustain operations until 2029. This financial stability is crucial as Crinetics prepares for significant milestones, including the anticipated PDUFA date for paltusotine in September 2025. The company is actively engaging with stakeholders in the acromegaly community and has launched CrineCARE, a support hub aimed at enhancing patient and provider connectivity.
Moreover, paltusotine is expected to receive a broad label and uniform reimbursement, which would facilitate its accessibility in both first-line and second-line treatment settings. Additionally, the European Medicines Agency has accepted the marketing application for paltusotine in acromegaly and granted it orphan designation, with a CHMP opinion expected in the first half of 2026. Crinetics is also advancing its atumelnant program, with updates on Phase 2 and 3 trials in congenital adrenal hyperplasia (CAH), including a pivotal Phase 3 trial design. These strategic developments and the robust pipeline contribute to the Buy rating for Crinetics Pharmaceuticals.

According to TipRanks, Jubinville, PhD is an analyst with an average return of -5.6% and a 40.00% success rate. Jubinville, PhD covers the Healthcare sector, focusing on stocks such as Liquidia Technologies, Tenaya Therapeutics, and Crinetics Pharmaceuticals.

In another report released today, Piper Sandler also maintained a Buy rating on the stock with a $97.00 price target.